Industry has flooded the US Food and Drug Administration's inbox with a bevy of recent submission announcements – too many to fit into a small introduction. So we'll skip the preamble this week and bring you right to the action:
Clinical-stage biopharma MorphoSys AG's relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL) combination treatment of tafasitamab and Revlimid (lenalidomide)...





